Castle Biosciences

Of the 32 companies in the index, 21 firms saw their stock prices increase, while 11 firms' share prices decreased. 

News items for the in vitro diagnostics industry for the week of Dec. 21, 2020.

The company said it will use the proceeds to support its operations, including the development of products in its pipeline, and for general corporate purposes.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The skin cancer diagnostics company said it delivered 7 percent more DecisionDx-Melanoma test results in Q3 2020 than in the previous year's third quarter.

The tests are covered when the patient has a personal history of melanoma and the test has demonstrated clinical and analytical validity.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The general LCD is covered for patients with a personal history of melanoma undergoing workups or being evaluated for treatment without metastatic disease.

Of the 28 companies in the index, 12 firms saw their stock prices increase, while 16 firms' share prices decreased. 

The skin cancer diagnostics company said it delivered 19 percent fewer DecisionDx-Melanoma test results in Q2 2020 than in the previous year's second quarter.